The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits.

NICIs ESTABLISH A NEW ATHEROSCLEROSIS DISEASE PARADIGM Our recent data in experimental mice and human cardiovascular tissues1,2 have provided information on a series of unexpected mechanistic insights into the pathogenesis of atherosclerosis.3-5 This body of evidence suggests a new disease paradigm of atherosclerosis progression. 35 These approaches could lead to vaccination strategies, antibody (B cell-based) treatment strategies and T cell therapies by engineering T cell receptors that specifically recognise disease-causing peptide sequences in bona fide atherosclerosis-specific autoantigens with the help of CRISPR-CAS9-gene engineered cells. However, since the NS uses the adventitia of all arteries as its main conduit to reach distant targets and indeed all parenchymal cells, we speculated that PNS axons may crosstalk to adventitia immune cells. [Extracted from the article]